Trial
NCT03013127
A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Oslo University Hospital
Collaborators
Italian Sarcoma Group; Merck Sharp & Dohme LLC
Condition
Osteosarcoma
Intervention
Pembrolizumab
Why stopped
Inclusion of patients was stopped because ≤2 patients had clinical benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-14